Research & Development
US FDA grants Emergency Use Authorisation to Cepheid's Xpert Xpress SARS-CoV-2
23 March 2020 -

The US Food & Drug Administration (FDA) has granted Emergency Use Authorisation (EUA) to United States-based Cepheid's Xpert Xpress SARS-CoV-2, a rapid molecular diagnostic test for qualitative detection of SARS-CoV-2, the virus causing COVID-19, it was reported on Saturday.

The test is intended to operate on any of the company's more than 23,000 automated GeneXpert Systems worldwide, with a detection time of around 45 minutes.

The company is to start shipping the test from next week.